Swiss National Bank Viking Therapeutics, Inc. Transaction History

Swiss National Bank

$146 Billion
Q4 2024

A detailed history of Swiss National Bank transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Swiss National Bank holds 196,200 shares of VKTX stock, worth $5.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

196,200

Previous 193,800 1.24%

Holding current value

$5.9 Million

Previous $12.3 Million 35.65%

% of portfolio

0.01%

Previous 0.01%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 10, 2025	BUY	$38.28 - $78.03 $91,872 - $187,272	2,400 Added 1.24%	196,200 $7.9 Million
Q3 2024 Nov 07, 2024	BUY	$49.84 - $70.47 $9,968 - $14,094	200 Added 0.1%	193,800 $12.3 Million
Q2 2024 Aug 08, 2024	BUY	$47.39 - $80.2 $1.18 Million - $2.01 Million	25,000 Added 14.83%	193,600 $10.3 Million
Q1 2024 May 07, 2024	BUY	$17.4 - $94.5 $17,400 - $94,500	1,000 Added 0.6%	168,600 $13.8 Million
Q4 2023 Feb 06, 2024	SELL	$9.24 - $19.64 $276,276 - $587,236	-29,900 Reduced 15.14%	167,600 $3.12 Million
Q3 2023 Nov 08, 2023	SELL	$10.92 - $16.0 $92,820 - $136,000	-8,500 Reduced 4.13%	197,500 $2.19 Million
Q2 2023 Aug 09, 2023	BUY	$14.84 - $24.79 $580,244 - $969,289	39,100 Added 23.43%	206,000 $3.34 Million
Q1 2023 May 10, 2023	BUY	$8.08 - $17.33 $1.35 Million - $2.89 Million	166,900 New	166,900 $2.78 Million
Q2 2022 Aug 09, 2022	SELL	$2.11 - $3.15 $351,315 - $524,475	-166,500 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$3.0 - $4.88 $33,600 - $54,656	11,200 Added 7.21%	166,500 $500,000
Q3 2021 Nov 08, 2021	BUY	$5.58 - $7.04 $56,358 - $71,104	10,100 Added 6.96%	155,300 $975,000
Q2 2021 Aug 06, 2021	SELL	$5.19 - $6.73 $24,912 - $32,304	-4,800 Reduced 3.2%	145,200 $870,000
Q1 2021 May 07, 2021	BUY	$5.74 - $9.67 $17,220 - $29,010	3,000 Added 2.04%	150,000 $949,000
Q2 2020 Aug 05, 2020	BUY	$4.35 - $8.08 $98,309 - $182,608	22,600 Added 18.17%	147,000 $1.06 Million
Q4 2019 Feb 06, 2020	BUY	$6.38 - $8.73 $30,624 - $41,904	4,800 Added 4.01%	124,400 $998,000
Q2 2019 Aug 02, 2019	BUY	$7.67 - $10.63 $18,408 - $25,512	2,400 Added 2.05%	119,600 $993,000
Q1 2019 May 10, 2019	BUY	$7.58 - $9.94 $42,448 - $55,664	5,600 Added 5.02%	117,200 $1.17 Million
Q4 2018 Feb 13, 2019	BUY	$7.16 - $16.21 $799,056 - $1.81 Million	111,600 New	111,600 $854,000

Others Institutions Holding VKTX

# of Institutions

468

Shares Held

65.8M

Call Options Held

5.84M

Put Options Held

3.76M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $2.31B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account

Swiss National Bank Viking Therapeutics, Inc. Transaction History